Deep Medicine Acquisition Corp.: directors' dealings · United States · SEC (Form 4)

About Deep Medicine Acquisition Corp.

Deep Medicine Acquisition Corp. is a United States-listed company quoted on the NYSE/NASDAQ ecosystem that was originally formed as a special purpose acquisition company, or SPAC. In other words, it was created not to run a traditional operating business, but to find and complete a merger, share exchange, asset acquisition, or similar business combination with one or more target companies. SEC filings show that Deep Medicine Acquisition Corp. was incorporated on July 8, 2020, in Delaware and completed its IPO on October 29, 2021. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1857086/000126493122000154/dmaq033122.htm?utm_source=openai)) The most important public development in the company’s history is its proposed business combination with TruGolf, Inc., announced in 2023 and later supported by an S-4 registration filing with the SEC. This is a key point for equity investors: Deep Medicine Acquisition Corp. should be understood primarily as a public-market transaction vehicle rather than as a standalone operating company with a long revenue history. The investment case, therefore, depends less on legacy operating metrics and more on deal execution, shareholder approvals, valuation, and post-transaction dilution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1857086/000149315223026482/ex99-1.htm?utm_source=openai)) Prior to the completion of its combination transaction, the company stated in SEC filings that it had no operating revenues and was focused on pursuing an initial business combination. Its filings also reference deadline extensions to consummate the transaction, which is common among SPACs when the acquisition process takes longer than originally planned. The company’s business address disclosed in SEC materials is 7951 S.W. 6th Street, Plantation, Florida, United States, indicating that its administrative base is in the United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1857086/000149315223040516/form10-q.htm?utm_source=openai)) From a competitive perspective, Deep Medicine Acquisition Corp. competes with other U.S. SPACs rather than with an industrial peer group. Its core “offering” is access to public capital markets, sponsor execution, and the ability to bring an emerging company onto a listed platform. As such, it does not have conventional products or services in the sense of an operating healthcare, technology, or consumer business. Instead, its principal corporate function has been to structure and complete a de-SPAC transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1857086/000126493122000154/dmaq033122.htm?utm_source=openai)) For French-speaking investors in France, Belgium, and Switzerland, the key takeaway is that Deep Medicine Acquisition Corp. is best analyzed as an event-driven special situation. The main notable public milestones are its formation, IPO, extension of the combination deadline, and the announced merger with TruGolf, rather than a mature operating history. Any forward-looking assessment should focus on the transaction structure and the resulting listed company profile after closing. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1857086/000149315223026118/forms-4.htm?utm_source=openai))